Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conflict Over Conflicts: FDA Advisory Committee Rules May Be Ripe For Change

This article was originally published in RPM Report

Executive Summary

Recruitment of FDA advisory committee members has been a persistent challenge for the agency—especially since the conflict of interest rules were tightened five years ago. While FDA has improved the number of vacancies on its expert panels, it has yet to meet its goals—especially in the Center for Drugs. Congress is considering loosening the restrictions. Will that help, or simply fuel criticism of the process?

You may also be interested in...



CDER Advisory Panel Vacancies Remain High As Overall FDA Rates Improve

Empty slots on CDER advisory panels holding agency back from meeting goal vacancy rate as other centers fill more panel slots.

Lone Wolfe: Drug Industry Critic Ends Tenure As Advisory Committee Member With Rare Decisive Vote

Sidney Wolfe’s stint as permanent member of the Drug Safety and Risk Management Advisory Committee ended May 31; his final meeting was the May 23 review of Xarelto for ACS. That gave him a second chance to vote against the product. A look back at Wolfe’s tenure shows he was a sure “no” vote when he sat on a panel—but that his service can hardly be construed as having damaged the industry.

An Emerging Approval Trend At FDA: More First-Time Sponsors

There is a surprising trend in the list of FDA approvals in 2011: an increase in the number of small biopharma companies opting to forgo Big Pharma partnerships and submit new product applications on their own. Here’s how these “emerging sponsors” are changing the way FDA does business—for big and small companies alike.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080977

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel